Target intelligence / Profile preview

Channel unblocking

Molecular classification
Pharmacological mechanism, Physiological process
01

Overview

Channel unblocking refers to the physiological or pharmacological process of removing a blocking agent from the pore of an ion channel, thereby restoring its ability to conduct ions. This term does not describe a specific protein or receptor but rather a functional transition or mechanism of action observed in various ion channels. A prominent biological example is the voltage-dependent magnesium (Mg2+) block of the N-methyl-D-aspartate (NMDA) receptor; depolarization of the postsynaptic membrane expels the Mg2+ ion, 'unblocking' the channel and allowing calcium influx, which is a fundamental requirement for synaptic plasticity and memory formation (Nowak et al., 1984). In clinical settings, channel unblocking is central to the reversal of neuromuscular blockade, where agents like Sugammadex act by encapsulating steroidal muscle relaxants, effectively 'unblocking' nicotinic acetylcholine receptors to restore muscle function (Naguid, 2007). Additionally, the therapeutic profile of drugs like memantine is defined by their 'unblocking' kinetics, where a relatively rapid rate of leaving the channel pore allows for the preservation of normal neurotransmission while preventing pathological overactivation (Parsons et al., 1999). Because it describes a functional event rather than a discrete biological entity, 'Channel unblocking' is considered a mechanism of action rather than a therapeutic target molecule.

Other names
Ion channel unblockingRelief of channel blockPore unblockingRecovery from block
02

Mechanism of action

Channel unblocking is a mechanism where an obstructing molecule or ion is removed from the pore of an ion channel, thereby restoring its conductive state and allowing the flow of ions across the cell membrane.

03

Biological functions

Synaptic plasticityNeuromuscular transmissionIon homeostasisVoltage-dependent signaling
04

Disease associations

Alzheimer's diseaseAnesthesia reversalMajor depressive disorderNeuromuscular disorders
05

Safety considerations

Excitotoxicity due to excessive ion influxRe-curarization (residual neuromuscular blockade)Cardiovascular instabilityPsychotomimetic effects
06

Interacting drugs

Sugammadex

4 more in the full profile.

07

Biomarkers

Train-of-four (TOF) ratioNMDA receptor occupancyElectroencephalogram (EEG) power spectra

Beyond the preview

Go deeper on Channel unblocking.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Channel unblocking.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call